Your browser doesn't support javascript.
loading
Evolution of antibody immunity following Omicron BA.1 breakthrough infection
Chengzi I. Kaku; Tyler N. Starr; Panpan Zhou; Haley L. Dugan; Paul Khalife; Ge Song; Elizabeth R. Champney; Daniel W. Mielcarz; James C. Geoghegan; Dennis R. Burton; Raiees Andrabi; Jesse D. Bloom; Laura M. Walker.
Affiliation
  • Chengzi I. Kaku; Adimab LLC, The Scripps Research Institute
  • Tyler N. Starr; Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center The University of Utah School of Medicine
  • Panpan Zhou; The Scripps Research Institute; International Aids Vaccine Initiative Neutralizing Antibody Center; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scr
  • Haley L. Dugan; Adimab LLC
  • Paul Khalife; Adimab LLC
  • Ge Song; Scripps Research Institute Immunology and Microbiology; Scripps Research Institute Immunology and Microbiology International Aids Vaccine Initiative Neutralizin
  • Elizabeth R. Champney; Adimab LLC
  • Daniel W. Mielcarz; Dartmouth-Hitchcock Norris Cotton Cancer Center
  • James C. Geoghegan; Adimab LLC
  • Dennis R. Burton; Scripps Research Institute Immunology and Microbiology; International Aids Vaccine Initiative Neutralizing Antibody Center; Consortium for HIV/AIDS Vaccine Deve
  • Raiees Andrabi; The Scripps Research Institute; International Aids Vaccine Initiative Neutralizing Antibody Center; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scr
  • Jesse D. Bloom; Fred Hutchinson Cancer Research Center, Howard Hughes Medical Institute University of Washington, University of Washington Department of Genome Sciences
  • Laura M. Walker; Invivyd Inc
Preprint in English | bioRxiv | ID: ppbiorxiv-508922
ABSTRACT
Understanding the evolution of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we tracked SARS-CoV-2 receptor binding domain (RBD)-specific antibody responses up to six months following Omicron BA.1 breakthrough infection in mRNA-vaccinated individuals. Cross-reactive serum neutralizing antibody and memory B cell (MBC) responses declined by two- to four-fold through the study period. Breakthrough infection elicited minimal de novo Omicron-specific B cell responses but drove affinity maturation of pre-existing cross-reactive MBCs toward BA.1. Public clones dominated the neutralizing antibody response at both early and late time points, and their escape mutation profiles predicted newly emergent Omicron sublineages. The results demonstrate that heterologous SARS-CoV-2 variant exposure drives the evolution of B cell memory and suggest that convergent neutralizing antibody responses continue to shape viral evolution.
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Prognostic study / Rct Language: English Year: 2022 Document type: Preprint
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Prognostic study / Rct Language: English Year: 2022 Document type: Preprint
...